TRINETRA › Sectors › Healthcare
Blue Jet Healthcare Limited (BLUEJET) — share price, P/E and fundamentals
Blue Jet Healthcare Limited (NSE: BLUEJET) closed at ₹504.55 on 30 Oct 2026, -22.8% over one year, against a 52-week range of ₹325.00 – ₹688.50.
In the quarter ended 30 Jun 2026 (standalone, filed 3 Aug 2026) it reported revenue of ₹293 cr and net profit of ₹78 cr, a 26.7% net margin; revenue fell 17.4% and profit fell 13.8% year on year.
On four consecutive filed quarters its trailing P/E is 37.3; since 14 May 2025 its own P/E has ranged from 19.3 to 57.4 (median 37.5), and today's reading is higher than 49% of those 362 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 23.0%, ROCE 30.2%, debt-to-equity 0.00, Piotroski F-score 7 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 90% of 63 sector peers; PBT margin higher than 94% of 63 sector peers; ROE higher than 82% of 63 sector peers.
Key figures
| Last close | ₹504.55 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -12.0% / +25.1% / -22.8% |
| 52-week low – high | ₹325.00 – ₹688.50 |
| Market capitalisation | ₹8,752 cr |
| Trailing P/E | 37.3 |
| Price / book | 6.44 |
| EV / EBITDA | 25.1 |
| Earnings yield | 2.7% |
| TTM EPS | ₹13.54 |
| TTM net profit | ₹235 cr |
| Quarter revenue | ₹293 cr |
| Quarter net profit | ₹78 cr |
| Net margin | 26.7% |
| Revenue growth (YoY) | -17.4% |
| Profit growth (YoY) | -13.8% |
| Return on equity | 23.0% |
| ROCE | 30.2% |
| Debt / equity | 0.00 |
| Current ratio | 4.21 |
| Free cash flow | ₹334 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹17.4 cr |
Against Healthcare peers
| Metric | BLUEJET | Peer median | Percentile |
|---|---|---|---|
| Net margin | 26.70 | 12.67 | 91 |
| PBT margin | 36.15 | 17.57 | 94 |
| ROE | 23.02 | 13.86 | 83 |
| ROCE | 30.16 | 16.59 | 86 |
| Debt / equity | 0.00 | 0.11 | 12 |
| Cash conversion | 1.35 | 1.25 | 59 |
| Trailing P/E | 37.26 | 43.26 | 34 |
| P/B | 6.44 | 5.88 | 57 |
Questions
What is the P/E ratio of Blue Jet Healthcare Limited?
Blue Jet Healthcare Limited's trailing P/E is 37.3, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 14 May 2025 its P/E has ranged 19.3–57.4.
What were Blue Jet Healthcare Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Blue Jet Healthcare Limited reported revenue of ₹293 cr and net profit of ₹78 cr (standalone), filed with the exchange on 3 Aug 2026.
What is Blue Jet Healthcare Limited's ROE?
Return on equity is 23.0% based on the balance sheet dated 31 Mar 2026.
Does Blue Jet Healthcare Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 31 Mar 2026.
What is BLUEJET's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, BLUEJET traded between ₹325.00 and ₹688.50.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: standalone SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.